Clinical Trial: PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension

U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07852403) titled 'PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension' on Sept. 15.

Brief Summary: Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease characterized by increased pulmonary vascular resistance, right ventricular dysfunction, and clinically important morbidity and mortality. Sleep-disordered breathing (SDB) and sleep-related hypoxemia are common in patients with PAH, but their prevalence, physiological determinants, longitudinal trajectories, prognostic significance, and potential role in individualized management remain incompletely defined.

PAH-SDB is a prospective, multice...